NEWS
Go back
ARCHIMED purchases BioVendor Group, a leading global player in advanced diagnostics
March
11,
2025
ARCHIMED purchases BioVendor Group, a leading global player in advanced diagnostics
Global private equity healthcare specialist ARCHIMED announces the acquisition of BioVendor Group, a major player in advanced diagnostics, with expertise in immunology, infectious, metabolic, and autoimmune diseases as well as genetics research, expanding ARCHIMED’s numerous investments in the diagnostics industry.
Founded in 1992 and headquartered in Brno, in The Czech Republic, BioVendor is a global integrated diagnostic player with production sites in Europe (Austria, Belgium, Spain, Slovakia and The Czech Republic). BioVendor immunoassays range from traditional 96-well-plate ELISA assays to more innovative CLIA and multiplex immunoblot technologies – all used to test for a highly diverse array of symptoms and diseases.
Immunoassay biochemical tests reveal the presence and concentration of molecules that are used to diagnose disease, based on interactions of antibodies with corresponding antigens. They lead to particularly early, accurate diagnostics, enabling effective treatment plans, better patient management and improved outcomes.
Using its proprietary sector analysis tool, MedSeg, ARCHIMED has identified immunoassays as a priority investment area. MedSeg tracks and analyzes over 430 sub-segments of the global healthcare industry.
BioVendor is part of a long line of diagnostics acquisitions for ARCHIMED, including DIESSE (returned 4.6 times investment after its sale in January), Eurolyser (returned 6x after its sale in 2022), SeqCenter and ZYTOMICS (both unrealized investments).
BioVendor was screened by ARCHIMED’s Diagnostics team and identified as a category leader through ARCHIMED’s proprietary MedDiscover approach as early as 2019. MedDiscover insights into BioVendor strengths played a key role in establishing a strong relationship with BioVendor management and shareholders, leading to the success of the current deal. Existing management will continue in its leadership role, benefitting from an attractive management package.
Working closely with management, ARCHIMED will deploy its MedValue template – ARCHIMED’s playbook for accelerating the growth of partnering companies – for development via internationalization (often including acquisitions), innovation and product range expansion. ARCHIMED will help materially bolster commercial efforts, as well as BioVendor’s already high-quality control & regulatory compliance capabilities.
The value-creation journey of BioVendor will be assisted by an experienced, new Board of Directors, including ARCHIMED Operating Partners and recruits from the MedTalents® network of ARCHIMED-associated senior healthcare executives who identify, facilitate and advise on deals and counsel ARCHIMED’s companies.
MedDiscover is a set of tools, processes and systems permitting ARCHIMED to identify and effectively engage with leading companies operating in ARCHIMED’s prioritized sub-sectors.
BioVendor is the seventh investment of ARCHIMED’s MED III fund, which closed on €650 million in 2021. The fund is now approximately half invested, exclusively through primary buyouts (none of its companies were previously owned by private equity). MED III targets small cap healthcare companies, typically valued at over €50 million and under €150 million, partnering with families, founders and management teams.
In terms of returns, ARCHIMED is ranked as the world’s 6th best performing Buyout firm in the latest Dow Jones-HEC ranking (out of 632 Buyout firms globally). ARCHIMED’s performance is particularly strong with regards to cash-to-cash returns, with a constant flow of liquidity events and distributions since inception, including in the last two years when most players struggled to provide liquidity.